Sapphire began testing 200 bladder cancer patient samples to test for the presence of QSOX1-related biomarkers. Utilizing Sapphire’s proprietary antibodies to test the bladder cancer samples, Sapphire developed a prototype rapid diagnostic test that measures levels of QSOX1 in blood.
About Sapphire Biotech
Sapphire Biotech was founded in 2019 to create novel Therapeutic approaches for cancer. Additionally, Sapphire plans to develop novel Diagnostics for early cancer detection, one of which is currently being evaluated in a clinical trial for its potential to diagnose pancreatic cancer. The company is currently formulating small molecules that target QSOX1, a master regulator of extracellular matrix and related secreted proteins. Located in San Diego, CA, Sapphire Biotech is privately held. For more information, please visit www.sapphirebiotech.com.